الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 206 |  |  |
| | | from | 206 | | |
Abstract
AMLs are infrequent, yet highly malignant neoplasms responsible for a large number of cancer-related deaths. While current treatment for AML is characterized by high response rates, patients’ long-term outcome is still disappointing.
Aim of the work: To measure PDL1 in denovo AML patients before receiving their induction chemotherapy to find out possible correlation between its expression and other diagnostic and prognostic parameters.
Patients and Methods : this study is prospective cohort study held between June 2016 to December 2017 included 40 patients who had denovo AML in Ain Shams University Hospitals.
Result: It was founded that the majority of study group (75%) expressed PD-L1 with surface expression in ≥20% blasts. This was not associated with difference between both groups-the negative and positive expressors- in terms of demographics, disease characteristics as peripheral blood as well as bone marrow findings, expression of different CD markers, cytogenetic risk group or treatment outcome including responsiveness to induction chemotherapy and overall survival. The only discrepancy between both groups was regarding initial hemoglobin level, as negative expressors exhibited lower hemoglobin values than positive expressors with a P-value of 0.049. Also, refractory patients enjoyed higher median expression of PD-L1 in relation to responders, but this did not show any statistical significance due to the low number of resistant cases being only 5.
Conclusion : there was overexpression of blast cells to PD-L1. Refractory patients had a higher median PD-L1 expression in relation to responders, but of no statistically significance (P value > 0.05)